I agree, all the other risks are just systematic risks that equally apply to all biotechs. Risk needs to be assessed ‘relative’ to other companies. Next hurdle or risk is does CPACS translate to the clinic. If you are invested you are of the opinion it will, unless you are looking for an AML (only) outcome.
Cardioprotection thread, page-854
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.68 |
Change
-0.030(1.75%) |
Mkt cap ! $286.2M | |||
| Open | High | Low | Value | Volume |
| $1.73 | $1.73 | $1.68 | $119.9K | 70.42K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3012 | $1.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 6382 | 1 |
View Market Depth
| Last trade - 15.07pm 03/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |